Comparison · NCT00458393-b3007456
TDF/FTC vs Placebo: Condomless Receptive Anal Intercourse in the Previous 12 Weeks With Any Partners Regardless of Status.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TDF/FTC vs Placebo: Condomless Receptive Anal Intercourse in the Previous 12 Weeks With Any Partners Regardless of Status. Trial comparisons, record NCT00458393-b3007456. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00458393-b3007456
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.304 | 0.278 | 0.332 | wilson | |
| Risk in group 2 | 0.312 | 0.286 | 0.34 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00808 | -0.0466 | 0.0305 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.974 | 0.86 | 1.1 | log | |
| Odds ratio, group 1 over group 2 | 0.963 | 0.804 | 1.15 | log | |
| Number needed to treat, for one fewer participant with the outcome on TDF/FTC than on Placebo | 124 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TDF/FTC | Daily oral emtricitabine/tenofovir disoproxil fumarate~Emtricitabine/tenofovir disoproxil fumarate: Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate | 332 | 1,091 | OG000 |
| Group 2 | Placebo | Daily oral placebo~Placebo: Placebo for emtricitabine/tenofovir disoproxil fumarate | 348 | 1,114 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Condomless Receptive Anal Intercourse in the Previous 12 Weeks With Any Partners Regardless of Status.
- Description
- Self-reported condomless receptive anal intercourse in the previous 12 weeks with any partners regardless of status.
- Time frame
- At 24 weeks
- Population
- Participants interviewed about sexual practices at week 24
Source ClinicalTrials.gov
Trial
- Title
- Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
- NCT number
- NCT00458393
- Phases
- PHASE3
- Conditions
- HIV Infections
- Interventions
- daily TDF/FTC, Placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2018-01-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00458393?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00458393-b3007456